Get the Stockscreener App
45.51
2.85%
1.26
After Hours:
45.50
-0.010
-0.02%
Boston Scientific Corp stock is traded at $45.51, with a volume of 20.03M.
It is up +2.85% in the last 24 hours and up +2.89% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$44.25
Open:
$44.6
24h Volume:
20.03M
Relative Volume:
0.97
Market Cap:
$67.64B
Revenue:
$20.62B
Net Income/Loss:
$3.56B
P/E Ratio:
19.08
EPS:
2.3847
Net Cash Flow:
$3.48B
1W Performance:
+3.98%
1M Performance:
+2.89%
6M Performance:
-51.38%
1Y Performance:
-57.12%
1-Day Range:
$44.59
$46.32
1-Week Range:
$42.50
$46.32
52-Week Range:
$42.20
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific to restructure, cut costs by $500M annually - NBC Boston
Fed. Circ. Clears Boston Scientific In $49M Stent Patent Case - Law360
Boston Scientific unveils new restructuring plan, expects job cuts - Reuters
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific (NYSE: BSX) sets $700–$800 million restructuring with $500 million savings - Stock Titan
Boston Scientific Overturns $42M Patent Verdict - Intellectia AI
Boston Scientific Gets $42 Million Stent Patent Verdict Reversed - Bloomberg Law News
Here's How Much $100 Invested In Boston Scientific 15 Years Ago Would Be Worth Today - Benzinga
Boston Scientific Corp (BSX) Cash Flow - TradingKey
Boston Scientific Corporation (BSX) Options Chain - Yahoo! Finance Canada
Boston Scientific Corp (BSX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Boston Scientific Corp (BSX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Boston Scientific (BSX) Faces FDA Advisory Over Transcarotid Sys - GuruFocus
Boston Scientific (BSX) Faces Potential Device Risk Notification - GuruFocus
Boston Scientific Corp (BSX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Boston Scientific Corp (BSX) Institutional Confidence - TradingKey
Boston Scientific Corp (BSX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - GlobeNewswire Inc.
BSX|Boston Scientific Corp|Price:45.500|Chg%:+1.250 - TradingKey
BSX|Boston Scientific Corp|Price:44.265|Chg%:+0.685 - TradingKey
Boston Scientific stock trades firm as cardiovascular revenue grows and TAVR momentum supports earni - AD HOC NEWS
Boston Scientific Corp (BSX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Daily Brief Health Care: Boston Scientific, Mitesco Inc, Samsung Biologics and more - Smartkarma
Boston Scientific (BSX) Enrolls First Patients In Global Faraflex AFib Trial - Yahoo! Finance Canada
AAFMAA Wealth Management & Trust LLC's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific stock trades steady as recent earnings and cardiovascular portfolio shape investor - AD HOC NEWS
Boston Scientific Settles With Stryker In Spine Device IP Fight - Law360
Goldman Sachs Launches $510 Million Autocallable Notes Linked to Boston Scientific Stock Performance - Kalkine Media
Boston Scientific Corporation (BSX) Stock forecasts - Yahoo Finance UK
Global Robotic Endoscopy Devices Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Boston Scientific, Stryker Settle Surgical Device Patent Dispute - Bloomberg Law News
Boston Scientific (BSX) Stock Still Looks Undervalued Following Its 58% Slump - Yahoo Finance
Boston Scientific stock trades steadily as device maker grows revenue and prepares for next earnings - Ad-hoc-news.de
Boston Scientific (BSX) Recalls Put Focus On Whether The Stock Still Looks Undervalued - Yahoo Finance
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Boston Scientific Corp. stock outperforms competitors despite losses on the day - MarketWatch
Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock? - Yahoo Finance
Boston Scientific stock advances on strong sales and margin gains - Ad-hoc-news.de
Boston Scientific to Combine Light Manufacturing, Global Distribution in Indiana Expansion - Assembly Magazine
Boston Scientific stock holds gains as cardiovascular revenue grows and new devices support long ter - Ad-hoc-news.de
Boston Scientific Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Boston Scientific Corp Investor Event at the Scientific Session of the American College of Cardiology Transcript - GuruFocus
Boston Scientific stock trades steady as latest earnings highlight growth and margin focus - ad-hoc-news.de
The Bull Case For Boston Scientific (BSX) Could Change Following Global Recall Of CRE Endoscopy Devices - simplywall.st
Boston Scientific stock trades steady as cardiovascular and neuromodulation growth supports earnings - ad-hoc-news.de
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific stock trades steadily as Q1 2026 growth and cardiology portfolio underpin valuatio - Ad Hoc News
Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Boston Scientific Expands Medical Device R&D in Ireland With €75 Million Investment - Assembly Magazine
Boston Scientific (BSX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Boston Scientific stock hits 52-week low at 42.24 USD By Investing.com - Investing.com South Africa
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):